Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Proteomics International Laboratories Ltd. ( (AU:PIQ) ) has shared an update.
Proteomics International Laboratories Ltd has expanded its collaboration with the University of Melbourne and the Royal Women’s Hospital to enhance the PromarkerEndo blood test for diagnosing endometriosis. This partnership aims to provide additional clinical validation and develop a next-generation tissue-specific test, addressing a significant global health need. The collaboration seeks to reduce the average seven-year diagnostic delay for endometriosis, potentially transforming women’s healthcare by offering a non-invasive diagnostic option. The agreement includes commercial terms granting Proteomics International an exclusive license to commercialize new intellectual property developed under the project.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a pioneer in precision diagnostics, focusing on developing innovative diagnostic tools. The company is known for its Promarker®Endo blood test, designed to diagnose endometriosis, a condition affecting one in nine women and girls worldwide. Proteomics International is committed to advancing precision medicine and improving diagnostic accuracy for complex diseases.
Average Trading Volume: 348,741
Technical Sentiment Signal: Sell
Current Market Cap: A$61.38M
For a thorough assessment of PIQ stock, go to TipRanks’ Stock Analysis page.